461 related articles for article (PubMed ID: 19355810)
1. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.
Anuurad E; Semrad A; Berglund L
Metab Syndr Relat Disord; 2009 Oct; 7(5):401-10. PubMed ID: 19355810
[TBL] [Abstract][Full Text] [Related]
2. Management of the metabolic effects of HIV and HIV drugs.
Brown TT; Glesby MJ
Nat Rev Endocrinol; 2011 Sep; 8(1):11-21. PubMed ID: 21931374
[TBL] [Abstract][Full Text] [Related]
3. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
Barbaro G
Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risks of antiretroviral therapies.
Mondy K; Tebas P
Annu Rev Med; 2007; 58():141-55. PubMed ID: 17217329
[TBL] [Abstract][Full Text] [Related]
6. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
Barbaro G
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
[TBL] [Abstract][Full Text] [Related]
7. HIV infection, antiretroviral therapy and cardiovascular risk.
Barbaro G
J Cardiovasc Risk; 2002 Oct; 9(5):295-300. PubMed ID: 12394324
[TBL] [Abstract][Full Text] [Related]
8. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
Barbaro G
Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
[TBL] [Abstract][Full Text] [Related]
9. The metabolic toxicities of antiretroviral therapy.
Herman JS; Easterbrook PJ
Int J STD AIDS; 2001 Sep; 12(9):555-62; quiz 563-4. PubMed ID: 11516363
[TBL] [Abstract][Full Text] [Related]
10. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
Calza L; Manfredi R; Chiodo F
Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
[TBL] [Abstract][Full Text] [Related]
11. [Metabolic disturbances associated with HAART].
Olczak A
Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and metabolic abnormalities among HIV-infected patients: a current review.
Kibirige D; Ssekitoleko R
Int J STD AIDS; 2013 Aug; 24(8):603-11. PubMed ID: 23970578
[TBL] [Abstract][Full Text] [Related]
13. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
[TBL] [Abstract][Full Text] [Related]
14. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment.
Stankov MV; Behrens GM
Endocr Metab Immune Disord Drug Targets; 2007 Dec; 7(4):237-49. PubMed ID: 18220944
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Grinspoon SK
Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
Feleke Y; Fekade D; Mezegebu Y
Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
[TBL] [Abstract][Full Text] [Related]
17. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients.
Barbaro G; Klatt EC
Curr Pharm Des; 2003; 9(18):1475-81. PubMed ID: 12769727
[TBL] [Abstract][Full Text] [Related]
18. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Nolan D
Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease and toxicities related to HIV infection and its therapies.
Zareba KM; Miller TL; Lipshultz SE
Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
[TBL] [Abstract][Full Text] [Related]
20. HIV and increased risk of cardiovascular diseases.
Das S
Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
